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REGULAR ARTICLE

Outcomes for patients with severe chronic neutropenia treated
with granulocyte colony-stimulating factor
David C. Dale,1 Audrey Anna Bolyard,2 James A. Shannon IV,2 James A. Connelly,3 Daniel C. Link,4 Mary Ann Bonilla,5 and
Peter E. Newburger6

Key Points




G-CSF is an effective
long-term therapy for
SCN with a wide
range of effective
doses requiring
individualized dose
titration.
Eleven percent of
patients with CN
developed MDS/AML;
patients with
autoimmune/idiopathic
neutropenia did not
develop myeloid
leukemia.

Severe chronic neutropenia (SCN), deﬁned as blood neutrophils ,0.5 3 109/L for .3 months,
is an uncommon hematological condition associated with recurrent and severe bacterial
infections. After short-term clinical trials showed the beneﬁts of granulocyte colony-stimulating
factor (G-CSF) treatment for SCN, SCNIR (Severe Chronic Neutropenia International Registry)
opened to determine the long-term beneﬁts and safety of this treatment. This report
summarizes ﬁndings from more than 16 000 patient-years of prospective observations for
patients with congenital and acquired SCN. We observed that adverse outcomes depend on the
underlying etiology. Myelodysplasia (MDS) and acute myeloid leukemia (AML) occur
infrequently and largely in patients with congenital neutropenias. Having cyclic or chronic
autoimmune/ idiopathic neutropenia portends a favorable prognosis. A few patients with
idiopathic neutropenia evolve to develop lymphoid malignancies, but they do not appear to be
at increased risk of myeloid malignancies, even with very long-term G-CSF therapy.
Progression to systemic autoimmune diseases, bone marrow (BM) failure, aplastic anemia, or
nonmyeloid malignancies are not expected consequences of SCN or treatment with G-CSF.

Introduction
Severe chronic neutropenia (SCN) is an uncommon hematological condition usually presenting with
fever, otitis, respiratory infections, gingivitis, and/or cellulitis.1 Granulocyte colony-stimulating factor
(G-CSF) was the ﬁrst predictably effective treatment for SCN, approved by the US Food and Drug
Administration (FDA) and the European Medicines Authority in 1994, based on a randomized controlled
trial.2 The approval required longitudinal follow-up with safety observations leading to the opening of the
SCNIR (Severe Chronic Neutropenia International Registry).3 Since 1994, the SCNIR has enrolled and
prospectively followed children and adults with minimal criteria of $3 absolute neutrophil counts (ANCs)
,0.5 3 109/L during a 3-month period. Follow-up was at least annually, recording signiﬁcant health
events and treatments. Patients were ineligible who had pancytopenia, aplastic anemia, myelodysplasia
(MDS), myeloid or lymphoid malignancy, systemic autoimmune diseases, or neutropenia due to idiosyncratic reactions to drugs or cancer chemotherapy.
We previously reported on the risk of MDS and acute myeloid leukemia (AML) in patients with congenital
neutropenia3-6 and longitudinal observations for other causes of SCN.7-11 For this report, we describe
long-term outcomes for all US patients enrolled in SCNIR. Almost all of the patients received G-CSF,
providing long-term data on the effectiveness and risks associated with this therapy.

Submitted 2 July 2021; accepted 6 April 2022; prepublished online on Blood Advances
First Edition 22 April 2022; ﬁnal version published online 1 July 2022. DOI 10.1182/
bloodadvances.2021005684.
Requests for data sharing may be submitted to David C. Dale (dcdale@uw.edu).
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Methods
This was a long-term prospective observational study of patients
enrolled from May 1994 to June 2020. The original cohort was
patients enrolled in the pivotal randomized trial.2 These patients
were recruited by physicians at academic centers. With the opening
of SCNIR, patients came from diverse sources (eg, adult and pediatric hematologists, primary care physicians, family members of
enrolled patients, and self-referral). All potential enrollees were evaluated uniformly and offered enrollment if they qualiﬁed. The research
was approved by the University of Washington Institutional Review
Board; all participants signed written informed consent.

Neutropenia. ANC ,0.5 3 10 /L on $3 occasions over $3
months. Patients were grouped into 3 main categories. Cyclic neutropenia required 2 ANC cycles with a nadir of ,0.2 3 109/L followed by increases usually to .1.0 3 109/L at approximately
3-week intervals. Congenital neutropenia was diagnosed based on
early childhood-onset and/or genetic test results and ANC remaining ,0.5 3 109/L beyond age 0.25 to 1.0 years. The autoimmune/
idiopathic category included all others and was divided into subgroups based on the diagnosis of the referring physician and results
of antineutrophil antibody testing performed through the ofﬁce of
the referring physician.
9

A bone marrow (BM) examination was originally required for enrollment. After about 10 years, the requirement for preenrollment BM
report was dropped for patients with cyclic and autoimmune/idiopathic neutropenia because it was contrary to usual practice and
because of the rarity of MDS or leukemia in these subgroups of
patients. Referring physicians, however, were encouraged to obtain
a marrow if, for any reason, it was clinically indicated.
Autoantibody testing. At the time of referral, clinicians were
encouraged to do antineutrophil antibody testing if the clinical diagnosis was autoimmune or idiopathic neutropenia, but these tests
were not required. Because of the lack of speciﬁcity and availability
of these tests, patients were enrolled as autoimmune neutropenia if
this was the referring physician’s diagnosis.12 Other results for autoantibodies were retrieved from clinical records.
Exclusion criteria. Diagnosis of drug-induced neutropenia (including chemotherapy), MDS, leukemia, aplastic anemia, HIV-associated
neutropenia, rheumatoid arthritis, systemic lupus erythematosus, and
other systemic autoimmune diseases.
Special groups. Patients with genetic disorders with neutropenia of varying severity (eg, Shwachman-Diamond syndrome [SDS],
glycogen storage disease type 1b [GSD1b], Barth syndrome,
Cohen syndrome, and Warts, Hypogammaglobulinemia, Infections,
and Myelokathexis [WHIM] syndrome) were enrolled to improve the
understanding of these disorders.
Treatment: G-CSF supply agreement. Amgen, originally the
exclusive supplier of G-CSF in the United States, provided ﬁlgrastim
to US patients enrolled in SCNIR who provided annual follow-up
data to build the safety proﬁle for the new drug. The dose and
schedule for G-CSF and other treatments were prescribed by the
patient’s physician, not by SCNIR. Subsequently, other G-CSF
3862
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Annual evaluations. A dedicated staff member followed up on
patients annually via e-mail, text, telephone, and letter with a standardized form for information on health, blood counts, infections,
malignancies, and hospitalizations. Initially, SCNIR requested physicians to provide this information but shifted to asking patients to
submit it to SCNIR, increasingly via internet communications. This
increased patient and family understanding of neutropenia and
increased the efﬁciency of reporting.
Oversight. An Advisory Board of physicians from the United
States, Australia, and Europe developed a handbook and website
with forms, diagnosis and treatment information, and treatment recommendations.13 Over time, more than 700 US physicians participated by enrolling and following SCNIR patients.

Results
Enrollment
From 1994 to 2020, the Seattle SCNIR ofﬁce received inquiries from
1799 physicians and 4544 patients or families about neutropenia
and enrollment in the SCNIR; 1752 patients met the criteria and
completed the registration in the following categories: congenital,
670 (38%); cyclic, 266 (15%); and autoimmune/idiopathic, 816
(47%). The overall mean follow-up was 9.3 years; 189 patients provided follow-up data for 15 to 20 years, 120 for 21 to 25 years, and
82 for .25 years; the longest participants came with data rolled over
from the randomized trial. There are more than 16 000 patient-years
of observational data, including those who died (1089 patient-years),
resolved neutropenia (2073 patient-years, largely children), received
hematopoietic stem cell transplants (HSCTs) (1629 patient-years,
483 of 1629 years from deceased patients), lost to follow-up (2028
patient-years), or withdrew from participation (645 patient-years) (see
Table 1). Overall outcomes of transplantation, evolution to malignancies, and or death were known for approximately 80% of the enrolled
patients; the percentages of lost-to-follow-up patients were: congenital, 18%; cyclic, 17%; autoimmune/idiopathic, 17%.

Patients
Symptoms of cyclic and congenital neutropenia were usually present soon after birth, but the diagnosis often followed a series of
acute febrile episodes because the infections resemble those of
other young children. In older children and adults, the diagnosis was
often made with routine blood counts when there were no symptoms of an infection at the time of the test. Table 2 shows ages at
onset of symptoms, diagnosis, and the start of G-CSF.

Genetic testing
When the SCNIR opened, genetic diagnosis by DNA sequencing
was just getting underway. Early SCNIR enrollees were critical for
ﬁnding mutations in ELANE as the predominant cause of cyclic and
congenital neutropenia.14,15 The congenital category enrolled in the
US ofﬁce of SCNIR now includes patients with mutations in ELANE
(333), SBDS (26), TAZ (25), COH1 (19), CXCR4 (11), SLC37A4/
G6PC (25), G6PC3 (4), WAS (5), TCIRG1 (21), CLBP (9),
SRP54 (3), VPS45 (1), and HAX (1). Testing for these mutations
12 JULY 2022 • VOLUME 6, NUMBER 13
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Enrollment criteria

suppliers were approved by the FDA; we included all available data
on G-CSFs for all suppliers in this report.

Table 1. Demographics
Congenital

Cyclic

Autoimmune/Idiopathic

Age, yr

<18

‡18

<18

‡18

<18

‡18

Patients

383

287

88

178

352

464

26.6

9.0

39.4

6.8

45.5

Age at last contact, yr

Median

Years of clinical observation study

8.5

Mean

8.7

30.0

9.4

42.3

7.9

46.8

Range

(0.3-17.9)

(18.0-82.0)

(1.2-17.9)

(18.1-92.8)

(1.1-17.9)

(18.0-90.7)

4.9

16.5

5.4

15.2

3.8

8.9

Mean

5.5

15.9

6.0

15.3

4.5

10.2

Range

(0-17.3)

(0-31.4)

(0-15.5)

(0.1-32.2)

(0-16.1)

(0-30.8)

4552

526

2722

1582

Years of observation by age

2119

Total years of observation by diagnosis*

6671

3248

4712
6294

*Total years of observation by all diagnostic groups: 16 213.

was performed in many different laboratories. Some mutations (eg,
JAGN1 and HAX1) were found rarely in the United States, although
observed more frequently in European and Middle Eastern populations.14,16 Financial and insurance barriers limit testing, so the majority of US patients did not have genetic testing.17

Autoimmune and idiopathic neutropenia
Patients were reported with autoimmune neutropenia if this was the
diagnosis assigned by the treating physician. Otherwise, these
patients were enrolled as idiopathic neutropenia. Across all groups,
we reviewed clinical testing for autoantibodies. The most frequent
test was antineutrophil antibody testing. Overall, 335 patients were
tested, of which 174 (52%) tested positive. There were positive
tests in all groups: cyclic, 3/17 (18%); congenital, 22/88 (25%);
and autoimmune/idiopathic 149/230, (65%). Other positive autoantibody results were antinuclear antibodies, 19/40 (47%); perinuclear
antineutrophil cytoplasmic antibodies, 5/28 (18%); antineutrophil
cytoplasmic antibodies, 2/28 (7%); proteinase 3, 2/11 (18%); and
antidouble stranded DNA, 1/9 (11%). Eighty-three percent of the
positive tests were in patients with autoimmune/idiopathic neutropenia, but testing was not systematic enough to allow the association

of speciﬁc results with outcomes. Lymphocyte counts were signiﬁcantly higher in childhood autoimmune/idiopathic neutropenia (,18
years) than in adults ($18 years); P , .0001.

G-CSF treatment, neutrophil, and lymphocyte counts
Because the patients had ANCs ,0.5 3 109/L and many had
recurrent fevers and infections, most were treated with G-CSF for
very long periods. Interruptions in G-CSF treatment predictably led
to reversion of the ANC to its baseline for most patients and recurrence of the same symptoms and problems that led to treatment.
The median ANCs with ranges at the time of enrollment in the
SCNIR for each group, pediatric and adult, are shown in Tables 2
and 3. The high counts that extend the ranges probably reﬂected
severe infections. G-CSF median treatment doses and responses
are also presented in Tables 2 and 3. For patients on alternate-day
or other than daily treatment, the doses were the calculated median
daily dose.
Many patients came to the SCNIR with histories of treatment with
diverse therapies, particularly in the early years of SCNIR, including
prophylactic antibiotics and glucocorticosteroids. It is difﬁcult to
evaluate the effectiveness of these therapies and their combinations,

Table 2. Age at onset and G-CSF treatment
Congenital
<18

Age, yr
Age at presentation, yr

Age at diagnosis, yr

Age at start of G-CSF treatment, yr

Age at enrollment, yr

Cyclic
‡18

<18

Autoimmune/Idiopathic
‡18

<18

‡18

Median

0.2

0.4

0.5

4.1

1.1

25.0

Mean

0.9

3.4

1.2

12.6

1.9

27.8

Range

(0-15.2)

(0-69.6)

(0-10.3)

(0-74.6)

(0-15.6)

(0-86.9)

Median

0.5

1.1

1.3

11.1

1.4

28.7

Mean

1.2

4.9

2.2

16.6

2.3

30.8

Range

(0-14.5)

(0-69.7)

(0-11.5)

(0-74.6)

(0-15.9)

(0-87.0)

Median

0.9

7.4

1.6

21.4

1.7

33.3

Mean

2.2

11.1

2.6

24.4

2.8

35.1

Range

(0-15.2)

(0-74.3)

(0.03-10.8)

(0.1-74.6)

(0.02-16.1)

(0.1-87.5)

Median

2.3

12.8

2.4

25.7

2.2

35.7

Mean

3.7

15.4

3.5

28.1

3.5

36.8

Range

(0.1-17.7)

(0.2-74.5)

(0.4-14.6)

(1.1-75.4)

(0.4-16.7)

(1.0-87.5)
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Median

Table 3. ANC* and ALC† before and on G-CSF treatment
Congenital
<18

Before G-CSF ALC

‡18

<18

‡18

<18

0.2

0.2

0.4

0.5

0.2

After G-CSF ANC

After G-CSF ALC

G-CSF treatment, yr

‡18
0.4

Mean

0.6

0.5

0.9

1.0

0.6

0.8

SEM

(60.05)

(60.05)

(60.07)

(60.07)

(60.04)

(60.04)

Range

(0-22.5)

(0-33.4)

(0-30.1)

(0-36.5)

(0-34.6)

(0-38.5)

Median

4.9

2.9

4.7

2.2

4.1

1.5

Mean

5.3

3.8

4.9

2.7

4.2

1.8

SEM

(60.13)

(60.15)

(60.1 9)

(60.13)

(60.10)

(60.05)
(0.04-54.6)

Range

(0.04-20.6)

(0.01-18.7)

(0.4-14.6)

(0.03-28.2)

(0.18-16.0)

Median

4.8

3.5

2.1

1.6

1.5

0.8

Mean

10.8

8.9

3.7

2.3

2.3

1.9

SEM

(61.04)

(61.12)

(60.69)

(60.15)

(60.13)

(60.15)
(0.01-42.9)

Range

(0.03-536.9)

(0.01-283.5)

(0.1-48.9)

(0.01-33.7)

(0.01-40.0)

Median

1.3

1.5

1.9

2.5

2.2

2.1

Mean

2.6

3.3

4.0

5.2

3.9

3.7

SEM

(60.12)

(60.14)

(60.36)

(60.29)

(60.16)

(60.13)

Range

(0-76.7)

(0-107.5)

(0-63.3)

(0-91.7)

(0-120.1)

(0-199.0)

Median

3.7

2.3

3.8

2.1

3.5

1.7

Mean

4.7

2.7

4.3

2.3

3.9

1.9

SEM

(60.12)

(60.09)

(60.22)

(60.05)

(60.10)

(60.05)

Range

(0.0-76.2)

(0.0-49.8)

(0.01-45.7)

(0.0-44.5)

(0.0-39.3)

(0.0-74.0)

Median

4.3

17.9

4.5

17.1

2.0

9.2

Mean

5.3

16.9

5.4

16.3

3.2

10.7

SEM

(60.22)

(60.52)

(60.48)

(60.70)

(60.17)

(60.37)

Range

(0-17.6)

(0-31.4)

(0-16.6)

(0-32.2)

(0-15.9)

(0-30.8)

*ANC 5 neutrophils 3 109/L.
†ALC 5 lymphocytes 3 109/L.

but it appears that they offered little beneﬁt and possible risks to
these patients.

chronic neutropenia reverted toward normal if infections and chronic
inﬂammation resolve.2,3

Table 3 shows ANC and absolute lymphocyte count (ALC) values for each patient category. Notably, the congenital group
had the lowest pre-G-CSF neutrophil counts, and this difference was statistically signiﬁcant compared with all groups
(ANOVA, P 5 .006). The mean G-CSF dose was highest in the
congenital group, though this was only statistically signiﬁcant
compared with the cyclic and autoimmune/idiopathic groups
(ANOVA; P , .0001). On G-CSF, the mean and median ANC
increased in all groups.

Fever, infections, and inﬂammation

Lymphocyte counts were generally within normal limits, but adult
patients with autoimmune/idiopathic neutropenia had lower ALCs
than the other patient groups (t test; P , .0001). For patients with
autoimmune/idiopathic neutropenia in SCNIR, none of the patients
who developed a lymphoproliferative disorder had lymphocytosis
or a diagnosis of large granular lymphocyte (LGL) leukemia at
enrollment.
As previously reported, patients with congenital neutropenia often
have moderate thrombocytosis, which reverts to normal on GCSF.2,3 In many cases, the mild anemia associated with severe

3864
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Before G-CSF, there was a typical pattern of fever and infections.
The most common events were fever, pharyngitis, otitis, bronchitis,
and mouth ulcers. Oral hygiene was hard to maintain; chronic gingivitis was a common and persistent problem, particularly in patients
with congenital neutropenia. Deep tissue infections (ie, pneumonia,
abscesses in the liver, spleen, or other tissues) were uncommon.
Cyclic neutropenia patients and others with very severe neutropenia
were at risk of developing peritonitis and sepsis syndrome.
Patients whose neutrophil counts increased predictably had decreased incidence of fever and infection-related events.2 We believe
this is the basis for patient acceptance of daily, alternate-day, or
thrice weekly G-CSF treatment, despite injection discomfort and
some bone pain. There was excellent adherence observed during a
long period when G-CSF vials were returned and counted. Hospital
records indicate that stays for infections decreased (before vs after
G-CSF), and death from infections decreased. There were 36
recorded deaths from infections during the 16 213 patient-years of
observation. These events were attributable to the failure to respond
12 JULY 2022 • VOLUME 6, NUMBER 13
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G-CSF dosing (mcg/kg per day)

Autoimmune/Idiopathic

Median

Age, yr
Before G-CSF ANC

Cyclic

Table 4. Patients with MDS or AML diagnosed before 1 January
2000 or on and after 1 January 2000
Before 01/01/2000

After 01/01/2000

29

48

77

10 (34)

8 (20)

18 (23)

Patients with MDS/AML
Patients with chemotherapy
only, n (%)
Living
Deceased
Lost to follow-up

Total

0

0

0

9 (90)

8 (100)

17 (90)

0

1

40 (83)

59 (77)

Living

5 (26)

18 (45)

23 (39)

Deceased

14 (74)

22 (55)

36 (61)

0

0

0

Lost to follow-up

to G-CSF (18 patients), insufﬁcient treatment (10 patients), or failure to maintain consistent treatment (8 patients). Deaths from infections were also complications of transplants or chemotherapy for
MDS or leukemia (Table 6).

Outcomes: myeloid malignancies
Overall, MDS or AML has occurred in 77/1752 (4.4%) of the
SCNIR-enrolled patients; 11.3% of the 670 congenital patients
developed MDS/AML. Table 4 summarizes outcomes for leukemia
treatments, dividing the events before and after 2000. This time
point was chosen because HSCT after chemotherapy became the
predominant mode of treatment around this time.18 The diagnoses
and number of affected patients were severe congenital neutropenia
(64; patients with or without known associate mutation), and others:
SDS (5), GSD1b (3), WAS (2), CXCR4/WHIMs (1), HAX1 (1),
and ELANE/cyclic neutropenia (1). There were no cases of AML/
MDS in patients with autoimmune/idiopathic neutropenia. The
median age at diagnosis of AML/MDS was 16.2 years (mean,
18.7 6 1.6; standard error of the mean [SEM] [range, 0.40-70.6]);
76 of 77 had been treated with G-CSF, median dose was 7.7
mcg/kg per day (mean, 12.2 6 1.3; SEM [range, 0.2-100]). The
G-CSF dose was signiﬁcantly higher in congenital patients evolving
to MDS and AML; congenital mean G-CSF, 9.6 6 0.84; SEM
(range, 0.16-234.7); congenital patients developing MDS/AML
mean G-CSF, 12.46 6 1.4 SEM (range, 0.6-56.5); P , .0001. It is
noteworthy that progression to AML/MDS was rare in patients with
cyclic neutropenia; patients were generally treated with lower doses
Table 5. Evolution to LPDs
Patients
Female/male
Total

Congenital

Cyclic

Autoimmune/
Idiopathic

305/365

145/121

573/243

670

266

816

Patients evolving to LPD
Patients evolving to LPD diagnosis

3

0

12

T-cell LPD

2

0

8

Non-Hodgkin lymphoma

1

0

3

Multiple myeloma

0

0

1

LPD, lymphoproliferative disease.

12 JULY 2022 • VOLUME 6, NUMBER 13

Treatment for AML in SCN patients has evolved over the period of
this study, with an increasing number of patients receiving HSCTs.
Outcomes for AML/MDS patients receiving chemotherapy with
HSCT before 2000 were poor, with 5/19 (26%) survivors (Table 4).
Since 2000, survivorship has almost doubled, increasing to 18/40
(45%). European investigators have reported higher survival rates
for transplantation after the development of leukemia as well as
transplantation for patients at high risk of developing leukemia.19,20
Three patients had other hematological malignancies: chronic myeloid leukemia in a congenital neutropenia patient, HSCT (living);
chronic lymphocytic leukemia in a cyclic neutropenia patient (living);
and chronic myelomonocytic leukemia in an autoimmune/idiopathic
neutropenia patient, HSCT (deceased).
Seven patients had reports of myeloﬁbrosis by BM examinations.
There were positive reports for 5 congenital and 2 autoimmune/idiopathic patients; the congenital patients were all from the early period
of SCNIR (ie, before 2000). One of the 5 patients with congenital
neutropenia (no known neutropenia-associated mutation) had 1 positive and 1 negative report of myeloﬁbrosis before enrollment, developed massive splenomegaly, and died of sepsis at 2 years of age.
The other 4 congenital neutropenia patients (all without known
neutropenia-associated mutations) had $1 report of myeloﬁbrosis
on BM examination. Two of these patients had multiple BM reports
showing inconsistent ﬁbrosis; 1 had 3 positive reports. The other
patient had 9 reports showing some evidence of ﬁbrosis and 10
reports not noting ﬁbrosis. The latter patient developed a T-cell lymphoproliferative disorder and died. Two of the 5 patients had a single positive report of myeloﬁbrosis, and 1 had 6 negative reports.
Both developed AML, 1 treated with HSCT, and both are now
deceased. The 2 patients (enrolled at ages 41 and 42) with the
diagnosis of chronic autoimmune/idiopathic neutropenia who developed myeloﬁbrosis had negative BM examinations before G-CSF
treatment; 1 patient had 3 reports, the other 1 report. One patient
was treated with HSCT (living), and 1 patient died of sepsis about
1 year after developing myeloﬁbrosis.

Outcomes: lymphoid malignancies
Fifteen of 1752 SCNIR patients developed lymphoid malignancies
(Table 5). Twelve of 816 (1.5%) patients developing lymphoid
malignancies occurred in patients with autoimmune/idiopathic neutropenia. These diagnoses at the time of enrollment were assigned
by the referring physician; these patients were listed as idiopathic
(11), autoimmune neutropenia (1), and congenital neutropenia (3).
None of the patients had clinical characteristics diagnosis of LGL
syndrome or LGL leukemia. The evolutions were primary to T-cell
disorders (see supplemental Table 1). Three of the 15 patients had
a positive test for antineutrophil antibodies. Among the 15 patients,
the median age at evolution to a lymphoid malignancy was 46.9
years (range, 17.5-77.6). Eight had T-cell lymphoproliferative disease, 3 had non-Hodgkin lymphoma, and 1 had multiple myeloma.
Twelve patients in the autoimmune/idiopathic group were deceased
due to severe lymphoproliferative disease and its complications.
Only 1 pediatric patient with autoimmune/idiopathic neutropenia
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1 (10)
19 (66)

Patients with chemotherapy
and HSCT, n (%)

of G-CSF than the congenital group (see Table 3). In the observational cohort of 3248 patient-years, the 1 ELANE/cyclic patient who
developed AML had also received long-term immunosuppressive
treatment for an unrelated illness.8

Table 6. Overall outcomes for patients with severe chronic neutropenia
Congenital
Patients
AML/MDS
HSCT, n (%)

Causes of death
Infection

Cyclic

Autoimmune/Idiopathic

Total
1752

670

266

816

76 (11.3%)

1 (0.01%)

0

77

127
(AML: 58;
neutropenia: 68, CML: 1)
(19.0%)

4
(AML: 1;
neutropenia: 3)
(1.9%)

6
(AML: 0;
neutropenia: 5; CMML: 1)
(1.0%)

137

92

24

43

159

21

7

8

36

11

2

1

14

AML with HSCT

35

1

0

36

AML without HSCT

16

1

0

17

Accident

0

2

0

2

LPDs

3

0

5

8

Cardiac

0

2

5

7

Unknown

4

3

12

19

1
(renal)

2
(1 colon,
1 hepatic)

4
(2 colon, 1 hepatic, 1 lung)

7

1

4

8

13

Nonmyeloid malignancies (cancer)

Other

CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; LPD, lymphoproliferative disease.

developed a T-cell lymphoproliferative disorder. Table 5 summarizes
these observations.
It is important to note that none of the 816 patients in the autoimmune/idiopathic or lymphoproliferative primary diagnostic groups
evolved to develop myeloid malignancies.

Other malignancies
Nonmyeloid and nonlymphoid malignancies were relatively rare, suggesting that severe chronic neutropenia does not predispose to
other malignancies. For the group of 1752 SCNIR patients, other
cancers have occurred mostly in older patients. They were dermatological malignancies (25; 7 before G-CSF, 18 on G-CSF), breast
cancer (17; 9 before G-CSF, 8 on G-CSF), colon cancer (6; 1
before G-CSF, 5 on G-CSF), ovarian/endometrial cancer (3; 1
before G-CSF, 2 on G-CSF), hepatic cancer (2, both on G-CSF),
renal cancer (1, on G-CSF), lung cancer (1, on G-CSF), prostate
cancer (1, before G-CSF), sarcoma (1, on G-CSF), and thyroid cancer (1, on G-CSF). Although we have observed common nonmyeloid malignancies, there is no apparent predisposition to these
malignancies in patients with a history of chronic neutropenia or as
a result of their long-term treatment with G-CSF.

Mortality
As expected, infections were the most common cause of death,
usually pneumonia, bacteremia, or sepsis syndrome, usually a consequence of severe neutropenia from failure to administer G-CSF,
lack of response to G-CSF, or as a complication of HSCT (Table
6). Patients with cyclic neutropenia remained at risk of death from
infections. Unfortunately, as noted above, these deaths and severe
infections were too often attributable to inconsistencies with G-CSF
treatment. Overall, autoimmune/idiopathic neutropenia patients have
a superior prognosis.

Discussion

Other adverse outcomes

SCN is an unusual hematological condition with many causes, both
hereditary and acquired.1,21 Its pathophysiology is complex1,14; the
common complications are recurrent and severe infections because
of inadequate delivery of neutrophils from the BM to the blood and
tissues.21 Most of these disorders result from the ineffective production of neutrophils.22 The hereditary disorders result in cell loss in
the developmental pathway from the promyelocyte to the mature
peripheral blood neutrophil.14 The acquired disorders are most
commonly considered autoimmune/idiopathic diseases, with autoantibodies or lymphocyte-derived cytokines impairing neutrophil production at the latter stages of their development.23

There were few other hematological complications in the 1752
patients. It is noteworthy that 4 patients in the autoimmune/idiopathic group developed systemic lupus erythematosus. Immune
thrombocytopenic purpura occurred in patients with congenital (2),
cyclic (2), and autoimmune/idiopathic (1) neutropenia. One patient
developed glomerulonephritis associated with chronic hepatitis.
Seven other patients developed chronic hepatitis (subtype information not available).

This report focuses on long-term outcomes for patients with SCN
treated with G-CSF, the dominant therapy for this condition for the
last 30 years. G-CSF therapy increases neutrophil counts for almost
all SCN patients. The breadth of this effect is attributable to this
cytokine’s capacity to stimulate neutrophil production, accelerate
neutrophil development, suppress neutrophil apoptosis, and cause
the near-immediate release of mature neutrophils from the BM into
the blood.24-26 Used preventively in SCN, G-CSF therapy decreases
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HSCT, not AML related

episodes of febrile neutropenia, antibiotic use, and infections.2 The
clinical beneﬁt is enormous: because of fewer febrile episodes,
G-CSF promotes well-being and increases productivity at work and
in school.27,28 There are now many reports on the effectiveness of
this therapy.29,30

Long-term SCNIR follow-up indicates that the risk for severe hematological outcomes (eg, myeloid malignancies) resides almost exclusively in patients with congenital neutropenia. In most cases, these
develop several years after the start of G-CSF. We have not
observed myeloid malignancies in the populations we classiﬁed as
autoimmune/idiopathic neutropenia, although others have reported
natural killer (NK) cell expansion, hairy cell leukemia, and MDS in
these patients.35 In this longitudinal study, we observed a few autoimmune/idiopathic patients who developed a lymphoproliferative disorder. However, the diagnostic workup was not uniform, but none
had elevated lymphocyte counts or other testing to indicate LGL
syndrome or LGL leukemia (Table 6).36-39 Our estimate of the frequency of a lymphoid malignancy in autoimmune/idiopathic neutropenia (12/816 [1.5%]) was higher than that for lymphoproliferative
malignancies in patients with systemic lupus erythematosus or
celiac disease,40,41 but lower than primary immune deﬁciency disorders.42 Our ﬁndings, however, are consistent with those of Fattizzo
and colleagues, who reported that 5 out of 76 patients with autoimmune/idiopathic neutropenia developed NK cell expansion and lymphoproliferative disorders.35 Based on increasing evidence for
T-cell–mediated suppression of myeloid cell development in both
idiopathic neutropenia and LGL syndrome, we believe adult idiopathic neutropenia and LGL syndrome may be overlapping conditions. For patients with adult-onset idiopathic neutropenia, we
recommend that clinicians characterize BM and blood lymphocyte
populations by ﬂuorescence-activated cell sorting analysis, examine
BM for clusters of lymphoid cells, and do gene rearrangement studies in challenging patients.
Our observations also underscore the differences in the conditions
called “autoimmune neutropenia” in children and adults.9,43 The
autoimmune/idiopathic children had higher lymphocyte count than
autoimmune/idiopathic adults and are far more likely than adults to
have spontaneous remissions. We have not observed a worsening
of neutropenia in children or adults with autoimmune neutropenia
with G-CSF treatment. On the other hand, we have not recorded a

12 JULY 2022 • VOLUME 6, NUMBER 13

We recognize the limitation of this study, including the incomplete
deﬁnition of the immunological status of patients with autoimmune/
idiopathic neutropenia, lack of genetic analyses for all patients, and
lack of standardization of the timing and reading of BM examinations. We have observed that over time BM examinations have
become less frequent in the United States, probably driven by
patient preference and costs. We believe that more support is
needed for genetic analyses and interpretations. Nevertheless, the
SCNIR has demonstrated the value of a registry to collect and longitudinally analyze data to describe clinical outcomes for patients with
rare diseases causing severe chronic neutropenia.44
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The SCNIR began as a safety study of the long-term effects of a
then-novel biological therapy.3 It steadily accrued records for sufﬁcient numbers of patients to report on patient safety and adverse
outcomes.4-8 From the beginning, the SCNIR was concerned about
the risk of leukemia, especially since most of the diseases being
treated were known to be associated, though rarely, with leukemic
transformation.14 For ELANE-associated neutropenia, there are speciﬁc mutations associated with more severe outcomes.7,31 The
mechanisms whereby certain mutations increase the risk of leukemic
transformation are gradually emerging.32,33 High doses of G-CSF
may be a risk factor for leukemic transformation, as we and others
have reported.34 However, the patients who require the largest
doses of G-CSF to achieve a neutrophil count .1.0 3 109/L are
the patients who appear to be at the greatest risk.

spontaneous remission in an adult patient (ie, $18 years at onset)
with the diagnosis of autoimmune or idiopathic neutropenia. Another
important observation is the infrequency of severe adverse events
associated with long-term G-CSF treatment. When we began
SCNIR, it was unknown if this potent growth factor would alter
growth or predispose malignancies. We have not observed either.
In the ﬁrst few weeks of G-CSF treatment, bone pain, myalgias, and
headaches were common, but these adverse effects largely disappeared with longer-term treatment, especially for patients on daily or
alternate-day therapy.
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